Curr Oncol Rep (2017) 19:64 DOI 10.1007/s11912-017-0627-0 BREAST CANCER (B OVERMOYER, SECTION EDITOR) Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 1,2,3 1,2,3 François Bertucci & Anthony Gonçalves Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The purpose of the review is to summarize the data regarding PD-L1 expression in breast cancer and the Despite considerable progresses over the past three decades, results of first clinical trials with PD-1 or PD-L1 inhibitors in 15% of patients with breast cancer still develop metastases patients with metastatic breast cancer. and die. Improved understanding of mammary oncogenesis Recent Findings PD-L1 expression is heterogeneous across has led to major therapeutic advances with the approval of primary breast cancers, and is generally associated with the several drugs targeting cancer cells. Examples include hor- presence of tumor-infiltrating lymphocytes and the presence mone therapy targeting the estrogen receptor (ER) pathway of poor-prognosis features such as high grade, and aggressive and targeted therapies directed against oncogenic proteins molecular subtypes (triple-negative (TN), basal, HER2- (HER2, EGFR, VEGF, PI3K/AKT/mTOR pathway, enriched). Early phase clinical trials using PD-1 or PD-L1 CDK4/6). Many other drugs are under development. inhibitors alone or in combination have shown objective
Current Oncology Reports – Springer Journals
Published: Aug 10, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera